ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Diagnostic performance and cost-effectiveness of a combined rapid antimicrobial susceptibility testing (RAST) and lateral flow immunochromatographic assay-based workflow for bloodstream infections.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the diagnostic performance, clinical impact, and cost-effectiveness of a workflow combining EUCAST rapid antimicrobial susceptibility testing (RAST) with lateral flow immunochromatographic assays (LFIA) for resistance detection directly from positive blood cultures (BCs).
methodsA single-center, retrospective study including 179 monomicrobial bloodstream infection (BSI) episodes was conducted. RAST results were compared with broth microdilution (BMD) as the reference method. LFIA performance was assessed for the detection of extended-spectrum β-lactamases (ESBLs) and carbapenemases. The impact on antimicrobial therapy was analyzed at predefined time points. A cost-effectiveness analysis using a decision tree model compared three strategies: matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS) identification plus RAST, MALDI-TOF MS plus LFIA and RAST, and the FilmArray BCID2 molecular panel.
resultsOverall categorical agreement between RAST and definitive AST was 98.2%, with a low rate of very major errors (n = 8). LFIA showed excellent performance, with 100% concordance for ESBL and carbapenemase detection. Antimicrobial therapy was modified in 54.2% of patients, with most changes occurring after direct identification and LFIA results. In 97% of cases with therapeutic modification, treatment was appropriate according to definitive AST. In the economic analysis, MALDI-TOF MS plus LFIA and RAST showed a favorable balance between cost (€34.32 per patient) and effectiveness (16.51 h gained), compared with MALDI-TOF MS plus RAST alone (€10.94; 15.11 h) and BCID2 (€160.60; 20.43 h). The incremental cost-effectiveness ratio for adding LFIA was €16.59 per hour gained.
conclusionThe combination of RAST and LFIA directly from positive BCs provides rapid, accurate, and cost-effective microbiological information, supporting early optimization of antimicrobial therapy and representing a practical alternative to molecular syndromic panels for BSIs.
Indexed as
Identifiers
42247015What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.